Literature DB >> 7042622

Radiosensitivity of human B-lymphocytic lymphomas in vitro.

L Johansson, J Carlsson, K Nilsson.   

Abstract

The radiosensitivity of four human B-lymphocytic lymphoma cell lines has been studied. For all lines the Do values were in the range 1.3 to 1.8 Gy. None of the survival curves had an appreciable shoulder. The extrapolation numbers varied in the range 1.0 to 1.2. Thus, the cell lines had a low capacity to accumulate sublethal damage. Furthermore, split dose experiments showed that no line had the capacity to repair sublethal damage. Taken together with earlier published experimental and clinical observations the results indicate that the use of an increased number of fractions in radiotherapy of B-lymphocytic lymphomas might be of great benefit to the patients. A schedule with an increased number of fractions will probably be as efficient in killing the tumour cells as previously used schedules but the tolerance of adjacent normal tissue will probably increase.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7042622     DOI: 10.1080/09553008214550451

Source DB:  PubMed          Journal:  Int J Radiat Biol Relat Stud Phys Chem Med        ISSN: 0020-7616


  4 in total

Review 1.  Investigational strategies in autologous stem cell transplantation for follicular lymphoma.

Authors:  Oliver Weigert; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; Christian Buske
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.

Authors:  Hong Song; Mohammad Hedayati; Robert F Hobbs; Chunbo Shao; Frank Bruchertseifer; Alfred Morgenstern; Theodore L Deweese; George Sgouros
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

3.  Changes in the repair ability of continuously irradiated lymphosarcoma LS/BL cells.

Authors:  V Jurásková; V Drásl
Journal:  Br J Cancer Suppl       Date:  1984

Review 4.  Current management of mantle cell lymphoma.

Authors:  Oliver Weigert; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.